Merck has launched a Phase 3 trial for subcutaneous pembrolizumab combined with berahyaluronidase alfa, achieving its primary goals.

Otsuka shared new information about Sibeprenlimab, an experimental monoclonal antibody aimed at treating IgA nephropathy in adults.

Nurix Therapeutics showcases early data on two programs for autoimmune and inflammatory diseases, NX-5948 and GS-6791, at ACR Convergence 2024.

Fate Therapeutics Showcases FT522, an Off-the-Shelf, ADR-Equipped CAR NK Cell Candidate, at the 2024 ACR Convergence.

Allogene Therapeutics shares preclinical findings for ALLO-329, a dual CAR T targeting CD19 and CD70, aimed at treating autoimmune diseases.

Lilly's tirzepatide lowered the chance of worsening heart failure events by 38% in adults who have HFpEF and obesity.

AbelZeta showcases preliminary findings on C-CAR168 for autoimmune disease treatment at ACR Convergence 2024.

Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.

AbbVie has obtained approval from the European Commission for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer.

Biosion has signed a global exclusive licensing deal with Aclaris Therapeutics for two promising immunology products that could be first-in-class and best-in-class.

Capstan Therapeutics showcases preclinical findings on its primary in vivo CAR-T candidate, CPTX2309, during the ACR Convergence 2024 event.

Neurogene has provided an update regarding its ongoing Phase 1/2 open-label clinical study assessing the NGN-401 gene therapy.